ATE244229T1 - Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren - Google Patents

Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren

Info

Publication number
ATE244229T1
ATE244229T1 AT97917801T AT97917801T ATE244229T1 AT E244229 T1 ATE244229 T1 AT E244229T1 AT 97917801 T AT97917801 T AT 97917801T AT 97917801 T AT97917801 T AT 97917801T AT E244229 T1 ATE244229 T1 AT E244229T1
Authority
AT
Austria
Prior art keywords
ulceration
matrix
ureas
thiadiazolyl
thio
Prior art date
Application number
AT97917801T
Other languages
English (en)
Inventor
E Jon Jacobsen
Mark A Mitchell
Heinrich Joseph Schostarez
Donald E Harper
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE244229T1 publication Critical patent/ATE244229T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Glass Compositions (AREA)
AT97917801T 1996-04-23 1997-04-10 Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren ATE244229T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1600396P 1996-04-23 1996-04-23
PCT/US1997/005428 WO1997040031A1 (en) 1996-04-23 1997-04-10 Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
ATE244229T1 true ATE244229T1 (de) 2003-07-15

Family

ID=21774823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917801T ATE244229T1 (de) 1996-04-23 1997-04-10 Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren

Country Status (9)

Country Link
EP (1) EP0900211B1 (de)
JP (1) JP2000509039A (de)
AT (1) ATE244229T1 (de)
AU (1) AU2603697A (de)
DE (1) DE69723258T2 (de)
DK (1) DK0900211T3 (de)
ES (1) ES2202602T3 (de)
PT (1) PT900211E (de)
WO (1) WO1997040031A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719385T2 (de) * 1996-06-21 2003-12-18 Pharmacia & Upjohn Co., Kalamazoo Mmp-hemmende thiadiazolylamide
CA2369666A1 (en) * 1999-04-07 2000-10-19 Santen Pharmaceutical Co., Ltd. N-substituted-n'-substituted urea derivatives and the use thereof as tnf-.alpha production inhibitory agents
DE19960640A1 (de) * 1999-12-16 2001-06-28 Aventis Pharma Gmbh Neue Stromelysin Inhibitoren
ES2200617B1 (es) * 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
JP4825375B2 (ja) * 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
DE102006047164A1 (de) * 2006-09-29 2008-04-03 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an 2-Isopropyl-5-Methyl-Cyclohexancarbonyl-D-Alaninmethylester und einem oder mehreren Hautbefeuchtungsmitteln
DE102006047160A1 (de) * 2006-09-29 2008-04-03 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit (R)-2-[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-propionsäure-methylester und einem oder mehreren Füllstoffen
DE102006047153A1 (de) * 2006-09-29 2008-04-03 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an 2-Isopropyl-5-Methyl-Cyclohexancarbonyl-D-Alaninmethylester und einem oder mehreren anti-entzündlichen Wirkstoffen
DE102006047163A1 (de) * 2006-09-29 2008-04-03 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an 2-Isopropyl-5-Methyl-Cyclohexancarbonyl-D-Alaninmethylester und einem oder mehreren Antioxidantien
DE102006047155A1 (de) * 2006-09-29 2008-04-03 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an 2-Isopropyl-5-Methyl-Cyclohexancarbonyl-D-Alaninethylester und einem oder mehreren Antioxidantien
DE102006047157A1 (de) * 2006-09-29 2008-04-03 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an 2-Isopropyl-5-Methyl-Cyclohexancarbonyl-D-Alaninmethylester und einem oder mehreren hautaufhellenden Wirkstoffen gegen unerwünschte Pigmentierung der Haut, insbesondere postinflammatorische Hyperpigmentierung
JP5580544B2 (ja) * 2009-03-25 2014-08-27 国立大学法人群馬大学 がん治療用の遊走阻害剤
EP2511510B1 (de) 2011-04-15 2014-10-08 Caterpillar Motoren GmbH & Co. KG Motorblock und Verbrennungsmotor mit einem Motorblock
EP2511511B1 (de) 2011-04-15 2016-05-11 Caterpillar Motoren GmbH & Co. KG Systemluftführungselement und Verbrennungsmotor mit einem Systemluftführungselement
EP2527610B1 (de) 2011-05-27 2015-03-18 Caterpillar Motoren GmbH & Co. KG SCR-Katalysator Sektion und ein Turbomotor damit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220954A (ja) * 1986-03-20 1987-09-29 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
BR9506535A (pt) * 1994-01-20 1997-09-16 British Biotech Pharm Inibidores de metaloproteinases
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase

Also Published As

Publication number Publication date
DE69723258T2 (de) 2004-01-29
JP2000509039A (ja) 2000-07-18
DE69723258D1 (de) 2003-08-07
DK0900211T3 (da) 2003-10-27
PT900211E (pt) 2003-10-31
WO1997040031A1 (en) 1997-10-30
EP0900211B1 (de) 2003-07-02
ES2202602T3 (es) 2004-04-01
AU2603697A (en) 1997-11-12
EP0900211A1 (de) 1999-03-10

Similar Documents

Publication Publication Date Title
MY117762A (en) Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation
ATE244229T1 (de) Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren
TNSN02013A1 (fr) Derives de benzothiadiazine, nouveaux inhibiteurs de metalloproteinases de matrice, et compositions les contenant
ATE175194T1 (de) (e)-20(22)-dehydrovitamin-d-verbindungen
GB8827305D0 (en) Compounds
DE69738740D1 (de) Verwendung von Oestrogen Antagonisten und Oestrogen Agonisten zur Behandlung von pathologischen Zuständen
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
YU40999A (sh) N-hidroksi-2-(alkil,aril ili heteroaril sulfanil,sulfinil ili sulfonil)-3-supstituisani alkil,aril ili heteroarilamidi, kao inhibitori za matrične metaloproteinaze
GR3025762T3 (en) Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents.
YU54896A (sh) (methilsulfonil)fenil-2-(5h)-furanoni kao cox-2 inhibitori
DE69510198D1 (de) Succinyl hydroxamsäure-, n-formyl-n-hydroxy-aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease-inhibitoren
NZ511885A (en) 2,3,4,5-tetrahydro-1H-[1,4]benzodiazephine-3-hydroxamic acid as matrix metalloproteinase inhibitors and as inhibitors of TNF-alpha converting enzyme (TACE)
ATE233251T1 (de) Mmp-hemmende thiadiazolylamide
TW363056B (en) Inhibition of matrix metalloproteases by substituted phenethyl compounds
FR2775976B1 (fr) Composition pharmaceutique ou cosmetique contenant un precurseur d'actif hydrolysable par la glucocerebrosidase
CA2244903A1 (en) Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation
DE60137023D1 (de) 2-thio-4h-3,1-benzoxazin-4-on derivate und ihre verwendung als enzyminhibitoren
SU1623149A1 (ru) Способ получения солей 2-имино-4-алкил(арил)тио-5,5-диалкил-2,5-дигидрофуранов
MX9709955A (es) Derivados del acido 5-pirazolilbenzoico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0900211

Country of ref document: EP

REN Ceased due to non-payment of the annual fee